Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report

BACKGROUND: Severe epistaxis is often difficult to control in patients with hereditary hemorrhagic telangiectasia (HHT). Propranolol has been shown to have antiangiogenic properties in vitro and in vivo and is commonly used to treat hemangiomas. We present our experience with topical nasal propranol...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei-Zahav, Meir, Blau, Hannah, Bruckheimer, Elchanan, Zur, Eyal, Goldschmidt, Neta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628419/
https://www.ncbi.nlm.nih.gov/pubmed/28978360
http://dx.doi.org/10.1186/s40463-017-0235-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628419/
https://www.ncbi.nlm.nih.gov/pubmed/28978360
http://dx.doi.org/10.1186/s40463-017-0235-x

Ejemplares similares